Aslan

Aslan's latest cancer focus also flops, leaving just two major programs for the troubled biotech
Aslan's latest cancer focus also flops, leaving just two major programs for the troubled biotech
Endpoints
Aslan
biliary tract cancer
clinical trials
gastic cancer
varlitinib
Flag link:
The Week Ahead In Biotech: Spotlight On ESMO Conference
The Week Ahead In Biotech: Spotlight On ESMO Conference
Yahoo/Benzinga
JNJ
daratumumab
Urogen
Rhythm Pharmaceuticals
Anavex
Aravive Biologics
TrovaGene
Incyte
AstraZeneca
Roche
Amgen
Aslan
G1 Therapeutics
GSK
Calithera Biosciences
Seattle Genetics
Immunomedics
Checkpoint Therapeutics
Aileron Therapeutics
Genocea Biosciences
AbbVie
Zymeworks
Flag link:
Upcoming events – Atara and Aslan await validating results
Upcoming events – Atara and Aslan await validating results
EP Vantage
Atara
Tab-cel
ATA188
multiple sclerosis
Aslan
varlitinib
Flag link:
Bristol-Myers reels back in an early-stage cancer drug prospect in $60M Asia deal
Bristol-Myers reels back in an early-stage cancer drug prospect in $60M Asia deal
Endpoints
Bristol-Myers Squibb
BMS-777607
Aslan
Asia
Flag link:
China Biotech Week In Review: Roche's China Strategy
China Biotech Week In Review: Roche's China Strategy
Seeking Alpha
Roche
China National Biotechnology Group
Aslan
Alios BioPharma
ImmunoBiology Ltd
Healthgen Biotechnology
Flag link:
Array BioPharma Licenses Cancer Drug ARRY-543 to ASLAN Pharmaceuticals
Array BioPharma Licenses Cancer Drug ARRY-543 to ASLAN Pharmaceuticals
Marketwatch
Array Biopharma
ARRY-543
Aslan
HER2 Inhibitor
cancer
Flag link: